Orgenesis Inc Total Liabilities
Orgenesis Inc total liabilities. Based on the latest financial reports, Orgenesis Inc (ORGS) has total liabilities worth $53.62 Million USD as of September 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Orgenesis Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Orgenesis Inc (2008–2023)
Total liabilities of Orgenesis Inc from 2008 to 2023. This chart illustrates how Orgenesis Inc's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Orgenesis Inc to see how much of total assets are deployed in long-term investments.
Orgenesis Inc Competitors by Total Liabilities
The table below lists competitors of Orgenesis Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alice QUEEN Ltd
AU:AQX
|
Australia | AU$1.48 Million |
|
Fanhua Inc
F:4CIA
|
Germany | €1.52 Billion |
|
RONSHINE CH.HLD.HD-00001
F:1R7
|
Germany | €87.92 Billion |
|
Trainline Plc
LSE:TRN
|
UK | GBX452.09 Million |
|
EAM Solar ASA
OL:EAM
|
Norway | Nkr8.52 Million |
|
City Chic Collective Ltd
AU:CCX
|
Australia | AU$68.62 Million |
|
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
NASDAQ:CUPR
|
USA | $3.45 Million |
|
Zenta Group Company Limited
NASDAQ:ZTG
|
USA | $407.14K |
Liability Composition Analysis (2008–2023)
This chart breaks down Orgenesis Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ORGS total asset value.
Liquidity & Leverage Metrics
Orgenesis Inc Total Liabilities Ratios Explained
Orgenesis Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.81 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Orgenesis Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Orgenesis Inc (2008–2023)
The table below shows the annual total liabilities of Orgenesis Inc from 2008 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $35.53 Million | +12.26% |
| 2022-12-31 | $31.65 Million | +49.24% |
| 2021-12-31 | $21.21 Million | -15.01% |
| 2020-12-31 | $24.96 Million | -71.12% |
| 2019-12-31 | $86.42 Million | +84.66% |
| 2018-12-31 | $46.80 Million | 0.00% |
| 2018-11-30 | $46.80 Million | +81.75% |
| 2017-12-31 | $25.75 Million | +12.40% |
| 2016-12-31 | $22.91 Million | -49.30% |
| 2015-12-31 | $45.19 Million | +764.30% |
| 2014-12-31 | $5.23 Million | +143.33% |
| 2013-12-31 | $2.15 Million | +553.63% |
| 2012-12-31 | $328.72K | +286.67% |
| 2011-12-31 | $85.01K | +612.12% |
| 2010-12-31 | $11.94K | +98.97% |
| 2009-12-31 | $6.00K | +71.43% |
| 2008-12-31 | $3.50K | -- |
About Orgenesis Inc
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of res… Read more